Implementation of a novel microarray-based diagnostic test for cancer of unknown primary
✍ Scribed by Ryan K. van Laar; Xiao-Jun Ma; Daphne de Jong; Diederik Wehkamp; Arno N. Floore; Marc O. Warmoes; Iris Simon; Wilson Wang; Mark Erlander; Laura J. van't Veer; Annuska M. Glas
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- French
- Weight
- 396 KB
- Volume
- 125
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Patients with carcinoma of unknown primary (CUP) present with metastatic disease for which the primary site cannot be found, despite extensive standard investigation. Here, we describe the development and implementation of the first clinically available microarray‐based test for this cancer type (CUPPrint), based on 633 individual tumors representing 30 carcinoma and 17 noncarcinoma classes. Tissue of origin prediction for either fresh frozen or paraffin‐embedded tumor samples is achieved with the use of a custom 8‐pack 1.9k microarray and robust classification algorithm. An expression profile of 495 genes was used to predict tumor origin by applying a k‐nearest neighbor algorithm. Internal cross‐validation and analysis of an independent, previously published, 229‐sample dataset revealed that clinically informative predictions were made for up to 94% of samples analyzed. Analysis of 13 previously published CUP specimens yielded predicted tumor origins that supported the clinical suspicion in 12 cases (92%). Microarray profiling presents a promising tool to assist in the identification of the primary tumor and might direct a more tailored treatment for CUP patients. © 2009 UICC
📜 SIMILAR VOLUMES
## Abstract The antigen‐induced leukocyte adherence inhibition (LAI) test is an assay of cellular immune reactivity which was expected to offer a promising adjunct to currently available diagnostic and monitoring procedures in cancer patients. We have applied this assay to (1) 83 inpatients clinica
## Abstract ## Background. Cidofovir has been reported to have activity against human papillomavirus (HPV) type 16, but no laboratory studies have been performed on HPV type 6, the main cause of recurrent respiratory papillomatosis (RRP). ## Methods. HPV6b E6 cDNA‐based C33A (non‐HPV cervical ca